Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Open accessAbstract
Cancer-on-chip (CoC) models, based on microfluidic chips harboring chambers for 3D tumor-cell culture, enable us to create a controlled tumor microenvironment (TME). CoC models are therefore increasingly used to systematically study effects of the TME on the various steps in cancer metastasis. Moreover, CoC models have great potential for developing novel cancer therapies and for predicting patient-specific response to cancer treatments. We review recent developments in CoC models, focusing on three main TME components: (i) the anisotropic extracellular matrix (ECM) architectures, (ii) the vasculature, and (iii) the immune system. We aim to provide guidance to biologists to choose the best CoC approach for addressing questions about the role of the TME in metastasis, and to inspire engineers to develop novel CoC technologies.
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that cancer-on-chip (CoC) models are increasingly used to study metastasis by controlling key tumor microenvironment (TME) components, especially anisotropic ECM, vasculature, and immune cells. It classifies CoC designs and highlights both their mechanistic and therapeutic potential and the remaining challenges for standardization, physiological fidelity, and clinical translation.
Key findings
- ECM stiffening and alignment are central to invasion: connective tissue around tumor-loaded mammary glands stiffens up to eight-fold (from 0.2 to 1.5 kPa), densifies, and straightens in murine cancer models and clinical biopsies. CoC models can generate anisotropic ECM via engineered, flow-derived, or cell-derived approaches, with collagen type I hydrogels tunable in stiffness (0.01–1 kPa) and porosity (0.2–15 μm pore diameters).
- Vasculature studies in CoC models show that TME cues modulate intravasation and extravasation: macrophage-secreted TNF-α increased endothelial permeability and enhanced cancer-cell invasion/intravasation; cyclic stretch mimicking breathing suppressed intravasation; paclitaxel reduced tumor growth; and CXCR2/CXCL5 regulation significantly altered extravasation.
- Immune components can be incorporated into CoC models: NK cells killed tumor cells in a dose-dependent manner and more efficiently with an immunotherapeutic antibody; CAR T cells entirely invaded breast and lung tumors and killed tumor cells over several days; TCR-engineered T-cell cytotoxicity decreased under hypoxic conditions; monocytes suppressed TCR T-cell cytotoxicity; and CAFs inhibited trastuzumab’s antitumor effect.
- Lymphoid organ models are emerging: a human artificial lymph node supported long-term experiments (14–30 days), and a bone-marrow-on-a-chip supported HSPC differentiation into monocytes and neutrophils, with breast-cancer cells invading both bone-marrow niches at a similar rate but not ECM-only chambers.
Methods
- Narrative review synthesizing and classifying recent CoC literature, with a focus on three TME components: anisotropic ECM architectures, vasculature, and the immune system.
- The paper reviews studies using four major CoC classes—compartmentalized channel, porous membrane, template-based, and self-assembly models—and lists experimental details in Table 1 and Table S1.
- No primary experiments, systematic search strategy, or quantitative meta-analysis are reported; the work is a literature synthesis and perspective.
Limitations
- The paper states that CoC models require standardization, industrial fabrication methods, standards for devices, cell seeding and validation protocols, and compatibility with pharmaceutical and clinical laboratories; current devices are designed for single or few tests, whereas many applications need large-scale testing.
- The paper states that oxygen supply through vessels is often not recapitulated, as most CoCs provide oxygen via culture medium or diffusion through chip materials; intra- and extravasation studies have concentrated on blood vessels, while lymphatic intravasation mechanisms are less explored; lymphoid OoC models lack lymph-node stromal cells; and adaptive immune cell incorporation requires donor matching.
- Evident from the text: as a narrative review, it does not provide a systematic appraisal or pooled effect estimates, and it notes that chip designs, materials, and fabrication approaches vary widely even within the four categories.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 123 cited sources checked · 0 supported · 0 flagged
- Premisecitation
Electrospinning or 3D microextrusion printing enable production of highly aligned collagen sheets or hydrogels with spaces estimated 2-20 μm between aligned fibrils.
“Furthermore, techniques such as electrospinning or 3D microextrusion printing enable the production of highly aligned collagen sheets, or hydrogels with spaces an estimated 2-20 μm between aligned fibrils [34,35].”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Preceding and accompanying invasion, cancer-associated fibroblasts (CAFs) may deposit fibronectin, collagen type I or type IV, or proteoglycans, resulting in stiffened, ECM-rich fibrous connective tissue.
“Preceding and accompanying invasion, cancer-associated fibroblasts (CAFs) may deposit fibronectin, collagen type I or type IV, or proteoglycans, resulting in stiffened, ECM-rich fibrous connective tissue [17,18].”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Collagen type I-based hydrogels enable tunable mechanical and structural properties, in particular stiffness (0.01-1 kPa) and porosity (0.2-15 μm pore diameters), by changes in concentration, polymerization conditions, or glycation.
“Collagen type I-based hydrogels enable tunable mechanical and structural properties, in particular stiffness (0.01-1 kPa) and porosity (0.2-15 μm pore diameters), by changes in concentration, polymerization conditions (such as pH or temperature changes), or glycation [26][27][28].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Premisecitation
ECM anisotropy is a hallmark in many cancers.
“Because ECM anisotropy is a hallmark in many cancers”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
Interstitial compartments are organized into various 3D architectures, including fibrillar porous networks or aligned bundles, heterogeneous in density, topology, and stiffness.
“Interstitial compartments are organized into various 3D architectures, including fibrillar porous networks or aligned bundles, heterogeneous in density, topology, and stiffness [11,12].”
Quote in the paperNot a substantial claim0 of 2 sources checked
- Premisecitation
Efforts have been made to design anisotropic matrix structures in CoC devices, particularly collagen type I, to recapitulate in vivo-like aligned collagen-rich ECM interacting with invasive tumors, using engineered, directional force-derived, or cell-derived approaches.
“More recently, however, efforts have been made to design anisotropic matrix structures (including in CoC devices) in particular, but not exclusively, collagen type I [24], with the aim of recapitulating in vivo-like aligned collagen-rich ECM interacting with invasive tumors [25] by using (i) engineered, (ii) directional force-derived, or (iii) cell-derived approaches (Figure 2A-C and Table 1).”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Cell traction deforms the ECM network from curvy and relaxed to stretched and linearized (anisotropic) architecture, typically aligned parallel or perpendicular to the tumor edge (TACS).
“The resulting cell traction then deforms the network from originally curvy and relaxed towards a stretched and linearized (anisotropic) architecture, which typically aligns in parallel or perpendicular orientation to the tumor edge, which is termed tumorassociated collagen signatures (TACS) (Figure 1) [19].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Not checked in the free run.
- Premisecitation
Alignment directs tumor invasion in hydrogels containing anisotropic structures generated by mechanical strain or by adding collagen-free tracks.
“it was recently demonstrated that alignment directs tumor invasion in hydrogels containing anisotropic structures”
Quote in the paperNot a substantial claim0 of 3 sources checked - Premisecitation
ECM orientation can be achieved by providing directional forces during or after fibril polymerization, such as external strain, flow, or shear.
“ECM orientation can be further achieved by providing directional forces during or after fibril polymerization, such as by external strain, flow, or shear [21,37,38].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Premisecitation
Engineered approaches account for controlled ECM architecture for studies of tumor growth and invasion.
“Engineered approaches account for controlled ECM architecture for studies of tumor growth and invasion [11].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] source
Not checked in the free run.
- Premisecitation
Stiffened ECM causes increased integrin signaling- and actomyosin contraction-mediated mechanocoupling.
“Stiffened ECM causes increased integrin signaling-and actomyosin contractionmediated mechanocoupling.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Not checked in the free run.
- Premisecitation
Breast cancer cells introduced into the vascular channel transmigrated across an endothelial monolayer into the osteo-cell compartment in a vascularized osteo-cell environment.
“Breast cancer cells were introduced into the vascular channel, which led to cancer cell transmigration across an endothelial monolayer into the osteo-cell compartment.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisenone given
Fibril space and stiffness can be controlled by adjusting flow rates or temperature during ECM assembly.
“Fibril space and stiffness can be controlled by adjusting flow rates or temperature during ECM assembly.”
Quote in the paperNot a substantial claim - Premisecitation
In a self-assembly model of vascularized human colorectal cancer, irregular, leaky, and ill-perfused microvasculature was observed to form within the tumor, a typical phenomenon for cancer microvasculature.
“In a self-assembly model of vascularized human colorectal cancer, irregular, leaky, and ill-perfused microvasculature was observed to form within the tumor, a typical phenomenon for cancer microvasculature (Figure 3C) [59].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [59] source
Not checked in the free run.
- Premisecitation
Regulation of the cancer cell surface receptor CXCR2 and bone-secreted chemokine CXCL5 significantly altered the extravasation rate.
“Regulation of the cancer cell surface receptor CXCR2 and bonesecreted chemokine CXCL5 significantly altered the extravasation rate.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisecitation
Some tumors co-opt existing vasculature and grow along the vessels until demand for nutrients and oxygen becomes too large and angiogenesis starts again.
“Instead of triggering angiogenesis, some tumors co-opt existing vasculature and grow along the vessels [53][54][55][56], until the demand for nutrients and oxygen becomes too large and angiogenesis starts again [53,55].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Interpretationreasoning
CoC models can be applied to investigate the influence of various cues on intravasation: chemical gradients, the presence of particular cells, mechanical stretch, as well as the effects of drugs.
“These examples show that CoC models can be applied to investigate the influence of various cues on intravasation: chemical gradients, the presence of particular cells, mechanical stretch, as well as the effects of drugs.”
Quote in the paperSubstantial claim - Interpretationreasoning
CoC models can be applied to emulate and study the interactions between a tumor and the vasculature, and their subsequent development, in a controlled fashion.
“These examples show that CoC models can be applied to emulate and study the interactions between a tumor and the vasculature, and their subsequent development, in a controlled fashion.”
Quote in the paperSubstantial claim - Premisecitation
Cyclic stretch of the porous membrane mimicking human breath motion suppressed the intravasation rate in an air-liquid interface lung cancer model.
“In this model, it was observed that the cyclic stretch of the porous membrane mimicking human breath motion suppressed the intravasation rate.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65] source
Not checked in the free run.
- Premisecitation
Different cancer cells (lung, breast, melanoma) flowed through the vascular channel disrupted the integrity of the BBB and extravasated, with the exception of liver cancer cells.
“A compartmental channel model was used to establish a blood-brain barrier (BBB) [74]; different cancer cells (lung, breast, melanoma) flowed through the vascular channel and were found to disrupt the integrity of the BBB and extravasate, with the exception of liver cancer cells.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisecitation
Extravasation is known to be influenced by various environmental factors, such as ECM heterogeneity, immune cells, EMT, integrins, blood flow, and biochemical gradients.
“Extravasation is known to be influenced by various environmental factors, such as ECM heterogeneity [4], immune cells [68], epithelial-to-mesenchymal transition (EMT) [69], integrins [70,71], blood flow [4,72], and biochemical gradients [73].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Premisecitation
Sprouting from the endothelial layer in the side channels into the middle compartment containing a tumor spheroid was triggered by the presence of fibroblasts in the spheroids.
“Sprouting from the endothelial layer in the side channels into the middle compartment containing a tumor spheroid was triggered by the presence of fibroblasts in the spheroids [58].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
- Premisecitation
Application of a chemotactic gradient of FBS around the blood vessel triggered the invasion of pancreatic cells and wrapping around the blood vessel prior to intravasation in a template-based model.
“Application of a chemotactic gradient of fetal bovine serum (FBS) around the blood vessel triggered the invasion of pancreatic cells, and the wrapping around the blood vessel prior to intravasation.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] source
Not checked in the free run.
- Premisecitation
Cancer-blood vessel interactions other than intravasation and extravasation have been examined using vascularized CoC models.
“Cancer-blood vessel interactions other than intravasation and extravasation have been examined using vascularized CoC models.”
Quote in the paperSubstantial claim - Premisecitation
Gradients (e.g., oxygen, other chemical factors) establish around blood vessels, which can influence the behavior of nearby tumor cells.
“factors) establish around blood vessels, which can influence the behavior of nearby tumor cells [47].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [47] source
Not checked in the free run.
- Interpretationreasoning
CoC models can be used to better understand cancer cell-vasculature interactions in critical steps of cancer progression, in particular intravasation and extravasation.
“Therefore, including the vasculature in CoC models is essential, and such models can be used to better understand cancer cell-vasculature interactions in critical steps of cancer progression, in particular intravasation and extravasation.”
Quote in the paperSubstantial claim - Premisecitation
A compartmental channels model of angiogenesis in a cancer spheroid was developed to study tumor perfusion and drug delivery.
“A compartmental channels model of angiogenesis in a cancer spheroid was developed to study tumor perfusion and drug delivery (Figure 3A) [57].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [57] source
Not checked in the free run.
- Interpretationreasoning
Different approaches exist to faithfully model in vivo-like ECM anisotropy and stiffness.
“Together, different approaches exist to faithfully model in vivo-like ECM anisotropy and stiffness, whereby the application of flow during matrix polymerization forms a particularly elegant combination for the formation of anisotropic patterns.”
Quote in the paperNot a substantial claim - Premisecitation
Tumors can induce angiogenesis from nearby blood vessels, triggered by hypoxia-induced HIF signaling and VEGF secretion by cancer cells in a growing tumor.
“In addition, there is crosstalk between (primary) tumors and blood vessels: tumors can induce angiogenesis from nearby blood vessels, which is triggered by hypoxia-induced hypoxia-inducible factor (HIF) signaling and vascular endothelial growth factor (VEGF) secretion by cancer cells in a growing tumor [48,49].”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Several studies have used CoC models to study and understand the effects of these cues on intravasation.
“Several studies have used CoC models to study and understand the effects of these cues on intravasation (Figure 3D-G).”
Quote in the paperNot a substantial claim0 of 3 sources checked - Interpretationreasoning
Adding complexity to CoC models may confound precise control over ECM parameters.
“Yet in adding complexity, precise control over the ECM parameters discussed earlier may be confounded.”
Quote in the paperNot a substantial claim - Premisecitation
TNF-alpha secretion by macrophages increased the permeability of the endothelial barrier, promoting tumor-cell intravasation.
“Furthermore, TNF-α secretion by macrophages increased the permeability of the endothelial barrier, promoting tumor-cell intravasation [64].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64] source
Not checked in the free run.
- Premisecitation
In a porous membrane device, B and T lymphocytes self-assembled into cellular clusters under flow, mimicking the formation of lymphoid follicles.
“Similarly, in a porous membrane device, B and T lymphocytes self-assembled into cellular clusters under flow (Figure 4D), mimicking the formation of lymphoid follicles”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [114]
Not checked in the free run.
- Premisecitation
In a breast cancer-on-chip model, natural killer-cell attraction was mediated by specific chemokine ligand/receptor interactions.
“In a breast CoC model, it was found that NK-cell attraction was mediated by specific chemokine ligand/receptor interactions [106].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [106] source
Not checked in the free run.
- Interpretationreasoning
These cancer-on-chip models do not recapitulate the critical effect of oxygen supply through vessels.
“these models therefore do not recapitulate the critical effect of oxygen supply through vessels”
Quote in the paperSubstantial claim - Premisecitation
T cell recruitment to tumor spheroids was increased in the presence of monocytes due to increased chemokine expression.
“T cell recruitment to tumor spheroids was shown to be increased in the presence of monocytes due to their increased chemokine expression [45].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [45] source
Not checked in the free run.
- Premisecitation
More dendritic cells migrated and infiltrated to treated tumor cells than to non-treated tumor cells.
“More DCs migrated and infiltrated to treated tumor cells than to non-treated tumor cells (Figure 4C)”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [107] source
Not checked in the free run.
- Premisecitation
Adding monocytes to the 3D hydrogel with tumor spheroids suppressed the cytotoxic effect of retrovirally transduced TCR T cells.
“Moreover, adding monocytes to the 3D hydrogel with tumor spheroids suppressed the cytotoxic effect of retrovirally transduced TCR T cells [110].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [110] source
Not checked in the free run.
- Premisecitation
The presence of cancer-associated fibroblasts promotes cancer-cell migration in lymphatic vessel devices.
“In a later study, the same group showed that the presence of CAFs promotes cancer-cell migration in these devices (Figure 4F), but the role of lymphatic endothelial cells (LECs) herein remains to be investigated [121,122].”
Quote in the paperNot a substantial claim0 of 2 sources checked - Interpretationreasoning
Building functional lymphoid organ-on-chip models including fibroblasts and endothelial cells to study cancer-cell metastasis is feasible.
“This study shows the feasibility of building functional lymphoid OoC models including fibroblasts and endothelial cells to study cancer-cell metastasis.”
Quote in the paperSubstantial claim - Premisecitation
First successes of immune therapy have proved that the patient's own immune system can be activated to destroy tumor cells.
“First successes of immune therapy have proved that the patient's own immune system can be activated to destroy tumor cells [86][87][88][89][90][91][92].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Premisecitation
An antitumor immune response starts within secondary lymphoid organs that drain the tumor, after which immune cells migrate to the tumor for cancer-cell elimination.
“An antitumor immune response will start within secondary lymphoid organs that drain the tumortumor-draining lymph nodes (tdLNs)after which immune cells migrate to the tumor for cancer-cell elimination [100].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [100] source
Not checked in the free run.
- Interpretationreasoning
These characteristics enable close emulation of the biological structure and function in the human body.
“These characteristics enable close emulation of the biological structure and function in the human body.”
Quote in the paperSubstantial claim - Premisecitation
Inflammatory neutrophils introduced in a microvascular network model increased tumor-cell extravasation.
“Also, inflammatory neutrophils were introduced in this model, which again increased tumor-cell extravasation [105].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [105] source
Not checked in the free run.
- Premisecitation
Factors in the tumor microenvironment, such as cancer-associated fibroblasts, can suppress the immune system.
“Also, factors in the TME, such as CAFs, can suppress the immune system.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [111] source
Not checked in the free run.
- Premisecitation
In a breast cancer-on-chip model, presence of cancer-associated fibroblasts inhibited the antitumor effect of the Her2 receptor-blocking antibody trastuzumab by preventing long cancer-immune cell interactions.
“In a breast CoC model, presence of CAFs inhibited the antitumor effect of the Her2 receptor-blocking antibody trastuzumab by preventing long cancer-immune cell interactions [111].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [111] source
Not checked in the free run.
- Interpretationcitation
Addition of fibroblasts to organ-on-chip models is required to fully recapitulate the lymphoid organ microenvironment.
“indicating that addition of fibroblasts to OoC models is required to fully recapitulate the lymphoid organ microenvironment”
Quote in the paperSubstantial claim - Premisecitation
Immune therapy studies are limited to particular cancer types and subsets of patients due to differences in mutation load and immune-related adverse effects.
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
Quote in the paperNot a substantial claim0 of 3 sources checked - Interpretationcitation
A suppressive tumor microenvironment generated either by myeloid cells or by fibroblasts affected by tumor cells, and its effect on an antitumor immune response, can be mimicked in cancer-on-chip models.
“Both these studies show that a suppressive tumor microenvironmentgenerated either by myeloid cells or by fibroblasts affected by tumor cellsand its effect on an antitumor immune response can be mimicked in CoC models.”
Quote in the paperSubstantial claim - Premisecitation
A bone-marrow-on-a-chip supported proliferation and differentiation of hematopoietic stem/progenitor cells into monocytes and neutrophils.
“BMoaC supported proliferation and differentiation of hematopoietic stem/progenitor cells (HSPCs) into monocytes and neutrophils.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [118] source
Not checked in the free run.
- Interpretationnone given
Studying the tumor-specific role of T cells in cancer-on-chip models is more challenging because it requires that T cells and tumor cells are derived from the same patient and the use of T cells able to recognize tumor-specific antigens.
“Studying the tumor-specific role of T cells in CoC models is more challenging as this requires that T cells and tumor cells are derived from the same patient and the use of T cells that are able to recognize tumor-specific antigens.”
Quote in the paperNot a substantial claim - Interpretationnone given
Cancer-on-chip models provide the means to introduce and control extracellular matrix alignment using various methods and to systematically study its effect on invasion and migration of cancer cells.
“CoC models provide the means to introduce and control ECM alignment using various methods, and to systematically study its effect on invasion and migration of cancer cells.”
Quote in the paperSubstantial claim
- May combine two claims. 45
- Classified as probably not a substantial claim. 27
- The quote only partly states this claim. 1
May combine two claims.
PremisecitationAs a result of collagen remodeling, connective tissues surrounding tumor-loaded mammary glands stiffen up to eight-fold (from 0.2 to 1.5 kPa), densify, and straighten with tumor formation, as detected in murine cancer models and clinical biopsies.
“As a result of collagen remodeling, connective tissues surrounding tumor-loaded mammary glands stiffen up to eight-fold (i.e., from 0.2 to 1.5 kPa), densify, and straighten with tumor formation, as detected in murine cancer models and clinical biopsies [20,21].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [20] source
Not checked in the free run.
- cites [21]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationLine patterns in the diameter range 50-100 μm can be realized by a lane configuration chip approach or photopatterning.
“Line patterns in the diameter range 50-100 μm, reflecting the diameters of smaller collagen fibers providing alignment to cells, can be realized by a lane configuration chip approach, or photopatterning, for example, using a photomask with UV light for hydrogel crosslinking [32,33].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [32]
Not checked in the free run.
- cites [33]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenThe vasculature can be included in CoC models in various ways to model tumor-vasculature interaction, intravasation, and extravasation.
“The vasculature is a key ingredient in any cancer model, and it can be included in CoC models in various ways to model tumor-vasculature interaction, intravasation, and extravasation.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenAnisotropic extracellular matrix (ECM) can be generated in CoC models using several methods.
“Generation of anisotropic extracellular matrix (ECM) is important in the context of cancer research and can be done in CoC models using several methods.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationInterstitial spaces between randomly organized collagen fibril networks in human or mouse dermis are in the range 1-20 μm; fibrillar collagen aligned along myofibers or nerve bundles in mice provide clefts in the range 2-30 μm in diameter.
“As examples, interstitial spaces between randomly organized collagen fibril networks in human or mouse dermis are in the range 1-20 μm; likewise, fibrillar collagen aligned along myofibers or nerve bundles in mice provide clefts in the range 2-30 μm in diameter [13,14].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [13]
Not checked in the free run.
- cites [14]
Not checked in the free run.
Classified as probably not a substantial claim.
Premisenone givenCoC models are based on microfluidic chips harboring chambers for tumor-cell culture that enable control over cellular composition of the TME, local gradients, fluid flow, and tissue mechanics.
“CoC models are based on microfluidic chips harboring chambers for tumor-cell culture that enable control over cellular composition of the TME, local gradients, fluid flow, and tissue mechanics.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationOriented fiber tracks mediate focal contact orientation and contact guidance along 'highways', ultimately leading to higher tumor incidence.
“oriented fiber tracks mediating focal contact orientation and contact guidance along 'highways', ultimately leading to higher tumor incidence [20,22,23].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [20] source
Not checked in the free run.
- cites [22]
Not checked in the free run.
- cites [23]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn the healthy organism, epithelial cells are positioned on a basement membrane composed mainly of collagen type IV and laminins, underlaid by interstitial tissue rich in collagen type I, elastin, and proteoglycans.
“In the healthy organism, epithelial cells are positioned on a basement membrane composed mainly of collagen type IV and laminins, which is underlaid by interstitial tissue rich in collagen type I, elastin, and proteoglycans [10].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10]
Not checked in the free run.
May combine two claims.
PremisecitationIn the TME, as a consequence of malignant transformation, cells break down the basement membrane and invade and remodel adjacent interstitial tissue.
“In the TME, as a consequence of malignant transformation, cells break down the basement membrane [15,16] and invade and remodel adjacent interstitial tissue (Figure 1).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [15]
Not checked in the free run.
- cites [16]
Not checked in the free run.
May combine two claims.
PremisecitationThe three TME components focused on (anisotropic ECM, vasculature, immune system) are relevant for developing ECM-targeting cancer treatments, evaluating drug dosing through the vasculature, and testing new immunotherapeutic strategies.
“Also, these components are relevant for developing ECM-targeting cancer treatments [6], to evaluate effectiveness of drug dosing towards the tumor through the vasculature [7,8], and to test new immunotherapeutic strategies [9].”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [6]
Not checked in the free run.
- cites [7]
Not checked in the free run.
- cites [8]
Not checked in the free run.
- cites [9]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenCoC models can be classified into four major types: compartmentalized channel, porous membrane, template-based, and self-assembly.
“CoC models can be classified into four major types, together allowing us to recapitulate key components of the tumor microenvironment (TME) relevant for our understanding of tumor development and for investigating potential therapies.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationECM anisotropy, crosslinking, and stiffening are interlinked, with each promoting local carcinoma invasion by enhancing integrin signaling.
“ECM anisotropy, crosslinking, and stiffening are interlinked, with each of them promoting local carcinoma invasion by enhancing integrin signaling”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [20] source
Not checked in the free run.
- cites [22]
Not checked in the free run.
- cites [23]
Not checked in the free run.
May combine two claims.
PremisecitationMore complex CoC models may harbor contractile CAFs and can be extended by adding endothelial or immune cells, supporting formation of multicell structures and processes in the TME.
“More complex CoC models may harbor contractile CAFs [40][41][42], and can be further extended by adding endothelial or immune cells [42][43][44][45][46], altogether supporting the formation of multicell structures and processes in the TME, such as vessels, fibroblast networks, or immune influx (Figure 1).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [40]
Not checked in the free run.
- cites [41]
Not checked in the free run.
- cites [42]
Not checked in the free run.
May combine two claims.
InterpretationreasoningFlow-derived generation of hydrogel anisotropy is a favorable methodology for CoC models because CoC models are designed to enable fluid flow.
“CoC models are designed to enable fluid flow, and as such, flow-derived generation of hydrogel anisotropy represents a very favorable methodology.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe formed microvessel network was perfusable and connected with the spheroid.
“The formed microvessel network was perfusable and connected with the spheroid.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [57]
Not checked in the free run.
- cites [58]
Not checked in the free run.
May combine two claims.
PremisecitationMeasurement of resulting fibril spacings can be quantified upon image analysis, and may range from 2-12 or 20 μm.
“Even though space generation between fibrils can be less controlled as compared with engineered ECM patterning approaches as outlined previously, the measurement of resulting fibril spacings can be quantified upon image analysis, and for instance may range from 2-12 or 20 μm [21,37,38].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [21]
Not checked in the free run.
- cites [37]
Not checked in the free run.
- cites [38]
Not checked in the free run.
May combine two claims.
PremisecitationIntravasation can be influenced or even triggered by multiple cues, including genetic, metabolic, or mechanical factors, or by cues in the TME such as oxygen tension, ECM, immune cells, and chemotactic gradients.
“Intravasation can be influenced or even triggered by multiple cues, including genetic, metabolic, or mechanical factors, or by cues in the TME such as oxygen tension, ECM, immune cells, and chemotactic gradients [60][61][62][63]”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [60]
Not checked in the free run.
- cites [61]
Not checked in the free run.
- cites [62]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSelf-assembly models for extravasation have been developed and used extensively.
“Self-assembly models for extravasation have been developed and used extensively (Figure 3I) [83,84].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [83] source
Not checked in the free run.
- cites [84]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationECM stiffness measurements in the 3D system may be obtained by Brillouin microscopy.
“ECM stiffness measurements in the 3D system may be obtained by Brillouin microscopy [39].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39]
Not checked in the free run.
The quote only partly states this claim.
Premiseown dataFlowing the chemotherapy drug paclitaxel through the microvessel network reduced tumor growth in a self-assembly model with patient-derived organoids and CAFs.
“In addition, the influence of flowing the chemotherapy drug paclitaxel through the microvessel network was studied, and it was found that this drug reduced tumor growth.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [67]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenECM networks in hydrogel-based 3D models can undergo secondary modification by cell-derived traction forces or proteolytic remodeling resulting in stretched and remodeled ECM structures.
“Intrinsic to most hydrogel-based 3D models, ECM networks can undergo secondary modification by cell-derived traction forces or proteolytic remodeling resulting in stretched and remodeled ECM structures.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSeveral studies have used compartmental channels or similar models for investigating extravasation.
“Several studies have used compartmental channels or similar models for investigating extravasation [80][81][82].”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationBecause of abnormally high and continuous expression levels of angiogenic factors in cancer, the vasculature becomes ill-defined; vessel wall unstable and highly permeable, architecture tortuous and irregularly shaped, and density increased.
“Because of the abnormally high and continuous expression levels of angiogenic factors in cancer, the vasculature becomes illdefined; the vessel wall is unstable and remains highly permeable, architecture of the vessel is tortuous and irregularly shaped, and the density of the vasculature is increased [50][51][52][53].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [50]
Not checked in the free run.
- cites [51]
Not checked in the free run.
- cites [52] source
Not checked in the free run.
May combine two claims.
PremisecitationCoC models can be applied to elucidate these effects, and researchers have developed vascularized CoC models to study extravasation to bone, brain, and other organs.
“CoC models can be applied to elucidate these effects, and researchers have developed vascularized CoC models to study extravasation to bone [74][75][76], brain [77,78], and other organs [79]”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [74]
Not checked in the free run.
- cites [75] source
Not checked in the free run.
- cites [76]
Not checked in the free run.
May combine two claims.
PremisecitationTNF-α secreted by macrophages increased endothelial permeability and enhanced cancer-cell invasion and intravasation in a compartmental channels model.
“By using the compartmental channels model, it was found that the proinflammatory cytokine tumor necrosis factor α (TNF-α) secreted by macrophages increased the endothelial permeability and enhanced cancer-cell invasion and intravasation (Figure 3D) [64].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64] source
Not checked in the free run.
May combine two claims.
PremisecitationThe increased permeability of the endothelial barrier promoted tumor-cell extravasation and subsequent invasion via microtracks generated by the invading monocytes.
“The increased permeability of the endothelial barrier promoted tumor-cell extravasation, and subsequently invasion via microtracks generated by the invading monocytes.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [103]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenPerfusion through side channels can establish chemokine gradients.
“Perfusion through side channels can establish chemokine gradients.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
InterpretationreasoningInclusion of innate immune cells in cancer-on-chip models is relatively simple because cells from different donors can be combined.
“Inclusion of innate immune cells in CoC models is relatively simple as cells from different donors can be combined.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationIn an alginate hydrogel in a cancer-on-chip device, natural killer cells were attracted by tumor spheroids, invaded the tumor spheroid, and induced tumor-cell killing.
“In an alginate hydrogel in a CoC device, NK cells were attracted by tumor spheroids where they invaded the tumor spheroid and induced tumor-cell killing [9].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenOoC models are based on microfluidic chips with micrometer-to millimeter-sized compartments and microchannels that enable controlled fluid transport.
“Organ-on-chip (OoC) models are based on microfluidic chips with micrometer-to millimeter-sized compartments and microchannels that enable controlled fluid transport.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe artificial lymph node system is now commercially exploited for drug screens before clinical trials.
“This system is now commercially exploited for drug screens before clinical trials [113].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [113]
Not checked in the free run.
May combine two claims.
InterpretationreasoningCoC models can be applied to directly observe and quantify extravasation, and to study the influence of cell type.
“These examples show that CoC models can be applied to directly observe and quantify extravasation, and to study the influence of cell type, but there is more potential to also investigate the influence of other TME components on this process.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationCancer cells secrete soluble factors that attract monocytes to tissues and drive differentiation into M1 and M2 macrophage subsets with antitumor or protumor functions, respectively.
“Cancer cells secrete soluble factors that attract monocytes to tissues, and here drive differentiation into M1 and M2 macrophage subsets with (respectively) antitumor or protumor functions.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [102]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisereasoningOoC compartments are optically accessible for live observation because chips are fabricated from transparent polymers.
“Further, the compartments are optically accessible for live observation as the chips are fabricated from transparent polymers.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationProinflammatory cytokines secreted by cancer-associated fibroblasts disrupt lymphatic vessel integrity, which could be reversed using blocking antibodies.
“One study found that proinflammatory cytokines secreted by CAFs disrupt lymphatic vessel integrity, which could be reversed using blocking antibodies [121], thereby confirming the involvement of these cytokines.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [121]
Not checked in the free run.
May combine two claims.
PremisecitationThe first human artificial lymph node consisted of an extracellular matrix containing lymphocytes and dendritic cells, incorporated in a bioreactor for perfusion of oxygen and cell culture medium containing lymphocytes, enabling long-term experiments of 14-30 days.
“The first human artificial LN [112] consisted of an ECM containing lymphocytes and DCs, incorporated in a bioreactor for perfusion of oxygen and cell culture medium containing lymphocytes, enabling long-term experiments (14-30 days).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [112]
Not checked in the free run.
May combine two claims.
PremisecitationBreast-cancer cells invaded both bone-marrow niches at a similar rate, but they did not invade extracellular-matrix-only chambers.
“Breast-cancer cells invaded both bone-marrow niches at a similar rate, but they did not invade ECM-only chambers.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [118]
Not checked in the free run.
May combine two claims.
PremisecitationUpon tumor growth, more immune cells appear as natural killer cells, macrophages and dendritic cells become part of the tumor microenvironment, while T cells are necessary for a proper antitumor immune response.
“Upon tumor growth, more immune cells appear, as natural killer (NK) cells, macrophages and dendritic cells (DCs) become part of the TME, while T cells are necessary for a proper antitumor immune response [98,99].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [98]
Not checked in the free run.
- cites [99] source
Not checked in the free run.
May combine two claims.
PremisecitationDifferent TCR-engineered T cells had different cytotoxic effects, and cytotoxicity decreased under hypoxic conditions.
“Different TCR-engineered T cells had different cytotoxic effects, and cytotoxicity decreased under hypoxic conditions [109].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [109]
Not checked in the free run.
May combine two claims.
PremisecitationTumors include fibroblasts and endothelial cells, and initially few immune cells.
“Besides cancer cells, tumors include fibroblasts and endothelial cells, and initially few immune cells [97].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [97]
Not checked in the free run.
May combine two claims.
PremisecitationIn a device enabling growth of large tumor masses, CAR T cells entirely invaded breast and lung tumors, proliferated, and killed tumor cells over several days under dynamic conditions.
“In a device enabling growth of large tumor masses, CAR T cells entirely invaded breast and lung tumors, proliferated, and killed tumor cells over several days under dynamic conditions [108].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [108] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisenone givenThe small size of OoC models allows high control of cellular and matrix composition, local biochemical gradients and flows, and mechanical forces.
“Their small size allows high control of the cellular and matrix composition, local biochemical gradients and flows, and mechanical forces.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenIn compartmentalized channel model, endothelial cells infused into a side channel can form an endothelial layer on the interface with hydrogel, mimicking the blood-vessel wall.
“Endothelial cells infused into a side channel can form an endothelial layer on the interface with hydrogel, mimicking the blood-vessel wall.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationSelf-assembly models can be used to track and quantify extravasation kinetics and to differentiate between morphological states such as initial tumor-cell protrusion past the endothelium and complete transmigration.
“Such models can be used to track and quantify the extravasation kinetics [84], and to differentiate between morphological states such as initial tumor-cell protrusion past the endothelium and complete transmigration.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [84]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
Premisenone givenCoC is a particular application of OoC which is increasingly used to obtain crucial insights into cancer development.
“Cancer-on-chip (CoC) is a particular application of OoC which is increasingly used to obtain crucial insights into cancer development.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
PremisereasoningOoC compartments can be used to reproducibly create an environment in which 3D cell-culture models can grow, develop, and interact within their own specified microenvironment, mimicking parts of human organs and tissues.
“The compartments can be used to reproducibly create an environment in which 3D cell-culture models can grow, develop, and interact within their own specified microenvironment, as such mimicking (parts of) human organs and tissues.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThese lymphoid organ-on-chip models all lack lymph node stromal cells and as such do not fully recapitulate the specialized microenvironments required for lymph node function.
“However, these lymphoid OoC models all lack LN stromal cells and as such do not fully recapitulate the specialized microenvironments required for LN function.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationDendritic cells efficiently phagocytosed treated tumor cells, which enabled tumor antigen presentation.
“Furthermore, DCs efficiently phagocytosed treated tumor cells [107], which enabled tumor antigen presentation.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [107]
Not checked in the free run.
May combine two claims.
PremisecitationLymphocytes in the artificial lymph node clustered together and responded to in vitro vaccination by secreting cytokines and antibodies.
“Lymphocytes clustered together and responded to in vitro vaccination by secreting cytokines and antibodies.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [112]
Not checked in the free run.
May combine two claims.
PremisecitationInflammatory monocytes introduced into a compartmental channels device destroyed endothelial tight junctions and invaded into the surrounding hydrogel where they differentiated towards macrophages.
“Once an endothelial monolayer was generated in a compartmental channels device, inflammatory monocytes were introduced, destroying endothelial tight junctions and invading into the surrounding hydrogel where they differentiated towards macrophages [103].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [103]
Not checked in the free run.
May combine two claims.
PremisecitationNatural killer cells killed tumor cells in a dose-dependent manner, and this was more efficient in the presence of an immunotherapeutic antibody.
“Here, NK cells killed tumor cells in a dose-dependent manner, and this was even more efficient in the presence of an immunotherapeutic antibody (Figure 4B).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [106]
Not checked in the free run.
May combine two claims.
PremisereasoningImmune cells in the tumor microenvironment not only kill tumor cells but can also support their metastatic behavior.
“Immune cells in the TME not only kill tumor cells but can also support their metastatic behavior.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningBoth the tumor microenvironment and the lymph node are important for the steering or suppression of the antitumor response.
“Thus, both the TME and the lymph node (LN) are important for the steering or suppression of the antitumor response.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Interpretationnone givenCancer-on-chip models can be classified into four major types, which together allow recapitulation of the key components of the tumor microenvironment relevant for understanding tumor development and for investigating potential therapies.
“CoC models can be classified in four major types, as shown in Figure 1, together allowing recapitulation of the key components of the TME relevant for understanding tumor development, as well as for investigating potential therapies.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Interpretationnone givenCancer-on-chip devices are designed to perform single or just a few tests simultaneously, whereas many applications require large-scale testing.
“in addition, the CoC devices are designed to perform single or just a few tests simultaneously, whereas many applications require large-scale testing.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
InterpretationreasoningTo fully represent the immune response in cancer-on-chip models, the lymph node must be included, with incorporation of lymphatic vessels to emulate tumor-lymphoid crosstalk.
“To fully represent the immune response in CoC models, the lymph node must be included, with incorporation of lymphatic vessels to emulate tumor-lymphoid crosstalk, and a few recent publications are working in this direction.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Interpretationown dataCurrent cancer-on-chip models can be categorized into four types, but specific chip designs, materials, and fabrication approaches are diverse even within these categories and vary between research laboratories, whereas large-scale implementation requires standardization.
“Figure 1B shows that the current CoC models can be categorized into four types, but the specific chip designs, the materials used, and the corresponding fabrication approaches are quite diverse even within these categories, and they vary between research laboratories, whereas large-scale implementation requires standardization”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.
InterpretationreasoningTo personalize cancer-on-chip models per patient case, a model should include all tumor microenvironment components relevant to the study to be done; specifically, for testing immunotherapies it is essential to use patient-matched adaptive immune cells (T lymphocytes).
“To reach this goal (or to personalize CoCs per patient case), a CoC model should include all TME components relevant to the study to be done, to provide an adequate representation; specifically, for testing immunotherapies it is essential to use patient-matched adaptive immune cells (T lymphocytes) in the CoC model.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenThe inclusion of the immune system in cancer-on-chip models is a relatively recent development.
“The inclusion of the immune system in CoC models is a relatively recent development.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningCancer-on-chip models have been mainly and successfully used to gain mechanistic insight into the role of specific tumor microenvironment components on tumor-cell behavior, but they can also be used to investigate the effect of cancer treatments.
“Taken together, CoC models have been mainly and successfully used to gain mechanistic insight into the role of specific TME components on tumor-cell behavior, but they can also be used to investigate the effect of cancer treatments.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationnone givenImmune cells have been added in cancer-on-chip models, and they have been shown to largely affect tumor development.
“Immune cells have been added in CoC models, and they have indeed been shown to largely affect tumor development.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone givenImmune cells can play a decisive role in tumor development, being able to act both as protumor and antitumor agents.
“immune cells can play a decisive role in tumor development, being able to act both as protumor and antitumor agents”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationcitationIncorporating immune cells in cancer-on-chip models is feasible and necessary for studying the antitumor immune response and the effect of immunotherapies.
“Together, incorporating immune cells in CoC models is feasible and necessary for studying the antitumor immune response and the effect of immunotherapies.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationnone givenCancer-on-chip models have been applied to understand the mutual influence between tumor and vasculature and to study intra- and extravasation under different conditions, such as the presence of immune cells and other cell types, dynamic strain, or biochemical gradients.
“CoC models have been applied to understand the mutual influence between tumor and vasculature, and to study intra-and extravasation under different conditions, such as the presence of immune cells and other cell types, dynamic strain, or biochemical gradients.”
Quote in the paperSubstantial claim
The paper relies on this without support.
Cancer progression and fatal outcome are rarely caused by the primary tumor, but by secondary tumors formed through metastasis.
“Cancer progression and fatal outcome are rarely caused by the primary tumor, but by secondary tumors formed through metastasis.”
The paper relies on this without support.
The characteristic tumor microenvironment plays a pivotal role in the metastatic steps.
“The characteristic tumor microenvironment (TME) has been indicated to play a pivotal role in these steps.”
The paper relies on this without support.
Most CoC models still start with randomly organized, porous 3D hydrogel cultures.
“To date, most CoC models still start with randomly organized, porous 3D hydrogel cultures.”
The paper relies on this without support.
The vasculature plays a pivotal role in tumor progression because it nurtures the tumor and provides a transportation route for cancer cells to circulate throughout the body.
“The vasculature plays a pivotal role in tumor progression since it nurtures the tumor and provides a transportation route for cancer cells to circulate throughout the body.”
The paper relies on this without support.
T cells cannot recognize tumor cells by themselves and need antigen-presenting cells such as dendritic cells and macrophages to present tumor-specific antigens to them.
“T cells cannot recognize tumor cells by themselves, and need antigen-presenting cellssuch as DCs and macrophagesto present tumor-specific antigens to them.”
The paper relies on this without support.
Cancer cells metastasize to lymphoid organs via lymphatic vessels.
“Cancer cells metastasize to lymphoid organs via lymphatic vessels.”
The paper relies on this without support.
The extracellular matrix forms the structural basis for the development of a reactive tumor microenvironment by harboring fibroblasts, blood and lymph vessels, allowing biochemical gradients to establish, and providing a substrate for the migration of fibroblasts, immune cells, and cancer cells.
“The ECM forms the structural basis for the development of a reactive TME by harboring fibroblasts, blood and lymph vessels, allowing biochemical gradients to establish, and providing a substrate for the migration of fibroblasts, immune cells, and cancer cells.”
The paper relies on this without support.
By extracellular matrix deposition, stiffening, and fiber alignment, the extracellular matrix fibers promote directed tumor invasion, a hallmark of many solid cancers.
“By ECM deposition, stiffening, and fiber alignment, the ECM fibers promote directed tumor invasion, a hallmark of many solid cancers.”
The paper relies on this without support.
The co-dependent interaction between cancer cells and newly developed blood vessels supports tumor growth and generates a transportation route for tumor cells to metastasize.
“the co-dependent interaction between cancer cells and (newly developed) blood vessels supports tumor growth and generates a transportation route for tumor cells to metastasize”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tumor chips can capture many features including cell-cell and cell-ECM interactions, mechanical forces within the ECM, central hypoxia, desmoplasia, gradients of nutrients, pH, and soluble factors.
“Tumor chips can capture many of these features, including cell-cell and cell-ECM interactions, mechanical forces within the ECM, central hypoxia, desmoplasia, gradients of nutrients, pH, and soluble factors (Koens et al., 2020; Miller et al., 2020; Jouybar et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Jouybar et al., 2023
The Abstract and the ECM in cancer-on-chip models section describe chips that control cell composition, biochemical gradients, tissue mechanics, and cell-driven ECM remodeling. The figure labeled Trends in Biotechnology lists nutrient and acidity gradients and dense ECM, while a model listed under Outstanding questions studies desmoplasia. However, the paper does not establish that chips capture *central* hypoxia; its discussion of oxygen gradients says most chips do not reproduce oxygen supply through vessels. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Blood-brain barrier model is cited to a bone-metastasis study
MinorThe text attributes a blood-brain barrier model to reference [74], but the paper's reference [74] is titled as a model of breast cancer metastasis to bone.
“A compartmental channel model was used to establish a blood-brain barrier (BBB) [74]; different cancer cells (lung, breast, melanoma) flowed through the vascular channel and were found to disrupt the integrity of the BBB and extravasate, with the exception of liver cancer cells.”
“74. Bersini, S. et al. (2014) A microfluidic 3D in vitro model for spec- ificity of breast cancer metastasis to bone. Biomaterials 35, 2454-2461”
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · see citing works
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101 · see citing works
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · see citing works
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 1× · see citing works
“Instead of triggering angiogenesis, some tumors co-opt existing vasculature and grow along the vessels [53 – 56], until the demand for nutrients and oxygen becomes too large and angiogenesis starts again [53,55].”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771 · see citing works
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296 · see citing works
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290 · see citing works
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · see citing works
Basement membranes: structure, assembly and role in tumour angiogenesis
Kalluri, R. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1094 · Cited by 1,748 · see citing works
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493 · see citing works
Wolf, K., te Lindert, M., Krause, M., Alexander, S., te Riet, J., Willis, A. L., Hoffman, R. M., Figdor, C. G., Weiss, S. J., & Friedl, P. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210152 · Cited by 1,375 · see citing works
Self-citationNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354 · see citing works
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962 · see citing works
Modelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906 · see citing works
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872 · see citing works
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809 · see citing works
Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation
Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., Charest, J. L., Moretti, M., & Kamm, R. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417115112 · Cited by 723 · see citing works
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works
Collagen-based cell migration models in vitro and in vivo
Wolf, K., Alexander, S., Schacht, V., Coussens, L. M., von Andrian, U. H., van Rheenen, J., Deryugina, E., & Friedl, P. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.08.005 · Cited by 637 · see citing works
Self-citationMechanoreciprocity in cell migration
van Helvert, S., Storm, C., & Friedl, P. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0012-0 · Cited by 587 · see citing works
Self-citationA microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone
Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C., Chung, S., Charest, J. L., Moretti, M., & Kamm, R. D. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.050 · Cited by 534 · see citing works
Interstitial flow influences direction of tumor cell migration through competing mechanisms
Polacheck, W. J., Charest, J. L., & Kamm, R. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103581108 · Cited by 509 · see citing works
Fluid forces control endothelial sprouting
Song, J. W., & Munn, L. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105316108 · Cited by 498 · see citing works
Brillouin microscopy: an emerging tool for mechanobiology
Prevedel, R., Diz-Muñoz, A., Ruocco, G., & Antonacci, G. (2019) · Nature Methods · doi:10.1038/s41592-019-0543-3 · Cited by 480 · see citing works
Hassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467 · see citing works
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · see citing works
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460 · see citing works
3D collagen alignment limits protrusions to enhance breast cancer cell persistence
Riching, K. M., Cox, B. L., Salick, M. R., Pehlke, C., Riching, A. S., Ponik, S. M., Bass, B. R., Crone, W. C., Jiang, Y., Weaver, A. M., et al. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.10.035 · Cited by 446 · see citing works
Chen, M. B., Whisler, J. A., Fröse, J., Yu, C., Shin, Y., & Kamm, R. D. (2017) · Nature Protocols · doi:10.1038/nprot.2017.018 · Cited by 385 · see citing works
A cancer cell metalloprotease triad regulates the basement membrane transmigration programPreprint
Hotary, K. B., Li, X.-Y., Allen, E. D., Stevens, S. L., & Weiss, S. J. (2006) · Genes & Development · doi:10.1101/gad.1451806 · Cited by 382 · see citing works
Oriented collagen fibers direct tumor cell intravasation
Han, W., Chen, S., Yuan, W., Fan, Q., Tian, J., Wang, X., Chen, L., Zhang, X., Wei, W., Liu, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610347113 · Cited by 376 · see citing works
Cell–cell adhesion and 3D matrix confinement determine jamming transitions in breast cancer invasion
Ilina, O., Gritsenko, P. G., Syga, S., Lippoldt, J., La Porta, C. A. M., Chepizhko, O., Grosser, S., Vullings, M., Bakker, G.-J., Starruß, J., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0552-6 · Cited by 375 · see citing works
Self-citationHIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372 · see citing works
Glentis, A., Oertle, P., Mariani, P., Chikina, A. S., Marjou, F. E., Atieh, Y., Zaccarini, F., Lae, M. E., Loew, D., Dingli, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00985-8 · Cited by 363 · see citing works
Intravital third harmonic generation microscopy of collective melanoma cell invasion
Weigelin, B., Bakker, G., & Friedl, P. (2012) · IntraVital · doi:10.4161/intv.21223 · Cited by 360 · see citing works
Self-citationvan den Eertwegh, A. J. M., Versluis, J., van den Berg, H. P., Santegoets, S. J. A. M., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K. U., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 355 · see citing works
Vascularized cancer on a chip: the effect of perfusion on growth and drug delivery of tumor spheroid
Nashimoto, Y., Okada, R., Hanada, S., Arima, Y., Nishiyama, K., Miura, T., & Yokokawa, R. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119547 · Cited by 332 · see citing works
Shirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316 · see citing works
A review of the development of tumor vasculature and its effects on the tumor microenvironment
Forster, J. C., Harriss-Phillips, W. M., Douglass, M. J. J., & Bezak, E. (2017) · Hypoxia · doi:10.2147/hp.s133231 · Cited by 315 · see citing works
Mechanisms of tumor cell extravasation in an in vitro microvascular network platform
Chen, M. B., Whisler, J. A., Jeon, J. S., & Kamm, R. D. (2013) · Integrative Biology · doi:10.1039/c3ib40149a · Cited by 308 · see citing works
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 303 · see citing works
Ray, A., Lee, O., Win, Z., Edwards, R. M., Alford, P. W., Kim, D.-H., & Provenzano, P. P. (2017) · Nature Communications · doi:10.1038/ncomms14923 · Cited by 293 · see citing works
Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device
Nashimoto, Y., Hayashi, T., Kunita, I., Nakamasu, A., Torisawa, Y.-S., Nakayama, M., Takigawa-Imamura, H., Kotera, H., Nishiyama, K., Miura, T., et al. (2017) · Integrative Biology · doi:10.1039/c7ib00024c · Cited by 266 · see citing works
Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity
Weigelin, B., den Boer, A. T., Wagena, E., Broen, K., Dolstra, H., de Boer, R. J., Figdor, C. G., Textor, J. C., & Friedl, P. (2021) · Nature Communications · doi:10.1038/s41467-021-25282-3 · Cited by 239 · see citing works
Self-citationA 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors
Pavesi, A., Tan, A. T., Koh, S., Chia, A., Colombo, M., Antonecchia, E., Miccolis, C., Ceccarello, E., Adriani, G., Raimondi, M. T., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89762 · Cited by 238 · see citing works
A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors
Xu, H. M., Li, Z., Yu, Y., Sizdahkhani, S., Ho, W. S., Yin, F., Wang, L., Zhu, G., Zhang, M., Jiang, L., et al. (2016) · Scientific Reports · doi:10.1038/srep36670 · Cited by 236 · see citing works
In vitro model of tumor cell extravasation
Jeon, J. S., Zervantonakis, I. K., Chung, S., Kamm, R. D., & Charest, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056910 · Cited by 233 · see citing works
Pericytes, an overlooked player in vascular pathobiology
Ferland-McCollough, D., Slater, S. C., Richard, J. S., Reni, C., & Mangialardi, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.008 · Cited by 231 · see citing works
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227 · see citing works
Sung, K. E., Yang, N., Pehlke, C., Keely, P. J., Eliceiri, K. W., Friedl, A., & Beebe, D. J. (2011) · Integr. Biol. · doi:10.1039/c0ib00063a · Cited by 226 · see citing works
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells
Donato, C., Kunz, L., Castro-Giner, F., Paasinen-Sohns, A., Strittmatter, K., Szczerba, B. M., Scherrer, R., Maggio, N. D., Heusermann, W., Biehlmaier, O., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108105 · Cited by 225 · see citing works
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221 · see citing works
Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0137 · Cited by 214 · see citing works
The functional role of integrins during intra- and extravasation within the metastatic cascade
Sökeland, G., & Schumacher, U. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0937-3 · Cited by 202 · see citing works
Oudin, M. J., & Weaver, V. M. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030817 · Cited by 198 · see citing works
Sapudom, J., Rubner, S., Martin, S., Kurth, T., Riedel, S., Mierke, C. T., & Pompe, T. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.022 · Cited by 195 · see citing works
Wallstabe, L., Göttlich, C., Nelke, L. C., Kühnemundt, J., Schwarz, T., Nerreter, T., Einsele, H., Walles, H., Dandekar, G., Nietzer, S. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126345 · Cited by 193 · see citing works
Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184 · see citing works
Chen, M. B., Hajal, C., Benjamin, D. C., Yu, C., Azizgolshani, H., Hynes, R. O., & Kamm, R. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715932115 · Cited by 183 · see citing works
Parlato, S., De Ninno, A., Molfetta, R., Toschi, E., Salerno, D., Mencattini, A., Romagnoli, G., Fragale, A., Roccazzello, L., Buoncervello, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01013-x · Cited by 181 · see citing works
Carey, S. P., Starchenko, A., McGregor, A. L., & Reinhart-King, C. A. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9565-x · Cited by 174 · see citing works
Liu, W., Song, J., Du, X., Zhou, Y., Li, Y., Li, R., Lyu, L., He, Y., Hao, J., Ben, J., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.053 · Cited by 174 · see citing works
A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling
Nguyen, D.-H. T., Lee, E., Alimperti, S., Norgard, R. J., Wong, A., Lee, J. J.-K., Eyckmans, J., Stanger, B. Z., & Chen, C. S. (2019) · Science Advances · doi:10.1126/sciadv.aav6789 · Cited by 172 · see citing works
Zanotelli, M. R., Rahman-Zaman, A., VanderBurgh, J. A., Taufalele, P. V., Jain, A., Erickson, D., Bordeleau, F., & Reinhart-King, C. A. (2019) · Nature Communications · doi:10.1038/s41467-019-12155-z · Cited by 165 · see citing works
The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model
Boussommier-Calleja, A., Atiyas, Y., Haase, K., Headley, M., Lewis, C., & Kamm, R. D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.005 · Cited by 158 · see citing works
A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime
Zhang, Q., Liu, T., & Qin, J. (2012) · Lab on a Chip · doi:10.1039/c2lc00030j · Cited by 151 · see citing works
Aung, A., Kumar, V., Theprungsirikul, J., Davey, S. K., & Varghese, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0342 · Cited by 146 · see citing works
Organ-on-a-chip model of vascularized human bone marrow niches
Glaser, D. E., Curtis, M. B., Sariano, P. A., Rollins, Z. A., Shergill, B. S., Anand, A., Deely, A. M., Shirure, V. S., Anderson, L., Lowen, J. M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121245 · Cited by 146 · see citing works
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model
Ayuso, J. M., Truttschel, R., Gong, M. M., Humayun, M., Virumbrales-Munoz, M., Vitek, R., Felder, M., Gillies, S. D., Sondel, P., Wisinski, K. B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1553477 · Cited by 142 · see citing works
LumeNEXT: A Practical Method to Pattern Luminal Structures in ECM Gels
Jiménez‐Torres, J. A., Peery, S. L., Sung, K. E., & Beebe, D. J. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500608 · Cited by 128 · see citing works
Metastasis of circulating tumor cells: Favorable soil or suitable biomechanics, or both?
Azevedo, A. S., Follain, G., Patthabhiraman, S., Harlepp, S., & Goetz, J. G. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1059563 · Cited by 126 · see citing works
Goyal, G., Prabhala, P., Mahajan, G., Bausk, B., Gilboa, T., Xie, L., Zhai, Y., Lazarovits, R., Mansour, A., Kim, M. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202103241 · Cited by 125 · see citing works
Hachey, S. J., Movsesyan, S., Nguyen, Q. H., Burton-Sojo, G., Tankazyan, A., Wu, J., Hoang, T., Zhao, D., Wang, S., Hatch, M. M., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01216e · Cited by 124 · cited 1× · see citing works
“In a self-assembly model of vascularized human colorectal cancer, irregular, leaky, and ill-perfused microvasculature was observed to form within the tumor, a typical phenomenon for cancer microvasculature (Figure 3C) [59].”
BackgroundMetastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches
Sleeboom, J. J. F., Eslami Amirabadi, H., Nair, P., Sahlgren, C. M., & den Toonder, J. M. J. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033100 · Cited by 122 · see citing works
Tumor-on-a-chip for integrating a 3D tumor microenvironment: chemical and mechanical factors
Wan, L., Neumann, C. A., & LeDuc, P. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00550a · Cited by 120 · see citing works
Organ-on-chip in development: Towards a roadmap for organs-on-chip
partners, T. O., Mastrangeli, M., Millet, S., & Raaij, J. V. D. E. (2019) · ALTEX · doi:10.14573/altex.1908271 · Cited by 116 · see citing works
Kim, H., Chung, H., Kim, J., Choi, D., Shin, Y., Kang, Y. G., Kim, B., Seo, S., Chung, S. H., & Seok, S. H. (2019) · Advanced Science · doi:10.1002/advs.201900195 · Cited by 116 · see citing works
p120-catenin-dependent collective brain infiltration by glioma cell networks
Gritsenko, P. G., Atlasy, N., Dieteren, C. E. J., Navis, A. C., Venhuizen, J.-H., Veelken, C., Schubert, D., Acker-Palmer, A., Westerman, B. A., Wurdinger, T., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0443-x · Cited by 112 · see citing works
Nerger, B. A., Brun, P.-T., & Nelson, C. M. (2019) · Soft Matter · doi:10.1039/c8sm02605j · Cited by 111 · see citing works
Characterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model
Lee, S. W. L., Adriani, G., Ceccarello, E., Pavesi, A., Tan, A. T., Bertoletti, A., Kamm, R. D., & Wong, S. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00416 · Cited by 109 · see citing works
Platel, V., Faure, S., Corre, I., & Clere, N. (2019) · Journal of Oncology · doi:10.1155/2019/8361945 · Cited by 101 · see citing works
Immunological substance testing on human lymphatic micro-organoids in vitro
Giese, C., Lubitz, A., Demmler, C. D., Reuschel, J., Bergner, K., & Marx, U. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.03.001 · Cited by 95 · see citing works
Mannino, R. G., Santiago-Miranda, A. N., Pradhan, P., Qiu, Y., Mejias, J. C., Neelapu, S. S., Roy, K., & Lam, W. A. (2017) · Lab on a Chip · doi:10.1039/c6lc01204c · Cited by 89 · see citing works
Microfluidic platform for studying osteocyte mechanoregulation of breast cancer bone metastasis
Mei, X., Middleton, K., Shim, D., Wan, Q., Xu, L., Ma, Y.-H. V., Devadas, D., Walji, N., Wang, L., Young, E. W. K., et al. (2019) · Integrative Biology · doi:10.1093/intbio/zyz008 · Cited by 88 · see citing works
Gong, M. M., Lugo-Cintron, K. M., White, B. R., Kerr, S. C., Harari, P. M., & Beebe, D. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119225 · Cited by 87 · see citing works
New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay
Wan, Z., Floryan, M. A., Coughlin, M. F., Zhang, S., Zhong, A. X., Shelton, S. E., Wang, X., Xu, C., Barbie, D. A., & Kamm, R. D. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202201784 · Cited by 84 · see citing works
The gate to metastasis: key players in cancer cell intravasation
Sznurkowska, M. K., & Aceto, N. (2021) · FEBS Journal · doi:10.1111/febs.16046 · Cited by 81 · see citing works
Ray, A., & Provenzano, P. P. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.05.004 · Cited by 80 · see citing works
Recapitulating the vasculature using ORGAN-ON-CHIP technology
Pollet, A. M. A. O., & den Toonder, J. M. J. (2020) · Bioengineering · doi:10.3390/bioengineering7010017 · Cited by 73 · see citing works
The importance of being a lumen
Bischel, L. L., Sung, K. E., Jiménez‐Torres, J. A., Mader, B. R., Keely, P. J., & Beebe, D. J. (2014) · The FASEB Journal · doi:10.1096/fj.13-243733 · Cited by 72 · see citing works
Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression
Bi, Y., Shirure, V. S., Liu, R., Cunningham, C., Ding, L., Meacham, J. M., Goedegebuure, S. P., George, S. C., & Fields, R. C. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa017 · Cited by 71 · see citing works
Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P. J., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900754 · Cited by 70 · see citing works
Marzagalli, M., Pelizzoni, G., Fedi, A., Vitale, C., Fontana, F., Bruno, S., Poggi, A. D., Dondero, A., Aiello, M., Castriconi, R., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.945149 · Cited by 63 · see citing works
Hypoxia pathway proteins and their impact on the blood vasculature
Rodriguez, D., Watts, D., Gaete, D., Sormendi, S., & Wielockx, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179191 · Cited by 62 · see citing works
The Use of Microfluidic Platforms to Probe the Mechanism of Cancer Cell Extravasation
Coughlin, M. F., & Kamm, R. D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901410 · Cited by 59 · see citing works
Lee, J., Kim, S.-E., Moon, D., & Doh, J. (2021) · Lab on a Chip · doi:10.1039/d1lc00182e · Cited by 58 · see citing works
Kutys, M. L., Polacheck, W. J., Welch, M., Gagnon, K. A., Koorman, T., Kim, S., Li, L., McClatchey, A. I., & Chen, C. S. (2020) · Nature Communications · doi:10.1038/s41467-020-17102-x · Cited by 56 · see citing works
Dynamics of 3D carcinoma cell invasion into aligned collagen
Ray, A., Morford, R. K., Ghaderi, N., Odde, D. J., & Provenzano, P. P. (2018) · Integrative Biology · doi:10.1039/c7ib00152e · Cited by 52 · see citing works
Mondadori, C., Crippa, M., Moretti, M., Candrian, C., Lopa, S., & Arrigoni, C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00907 · Cited by 50 · see citing works
Biomimetic on-a-chip platforms for studying cancer metastasis
Lee, E., Song, H.-H. G., & Chen, C. S. (2015) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2015.12.001 · Cited by 49 · see citing works
Darrasse-Jèze, G., & Podsypanina, K. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00292 · Cited by 48 · see citing works
Rapid fabrication of collagen bundles mimicking tumor-associated collagen architectures
Gong, X., Kulwatno, J., & Mills, K. L. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.019 · Cited by 43 · see citing works
Engineering fiber anisotropy within natural collagen hydrogels
Ahmed, A., Joshi, I. M., Mansouri, M., Ahamed, N. N. N., Hsu, M.-C., Gaborski, T. R., & Abhyankar, V. V. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00036.2021 · Cited by 41 · see citing works
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival
Lamaison, C., Latour, S., Hélaine, N., Morvan, V. L., Saint-Vanne, J., Mahouche, I., Monvoisin, C., Dussert, C., Andrique, L., Deleurme, L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003949 · Cited by 38 · see citing works
Sleeboom, J. J. F., den Toonder, J. M. J., & Sahlgren, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103047 · Cited by 34 · see citing works
Continuous formation of ultrathin, strong collagen sheets with tunable anisotropy and compaction
Malladi, S., Miranda-Nieves, D., Leng, L., Grainger, S. J., Tarabanis, C., Nesmith, A. P., Kosaraju, R., Haller, C. A., Parker, K. K., Chaikof, E. L., et al. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00321 · Cited by 34 · see citing works
Su, C., Chuah, Y. J., Ong, H. B., Tay, H. M., Dalan, R., & Hou, H. W. (2021) · Biosensors · doi:10.3390/bios11120509 · Cited by 33 · see citing works
Intratumoral phenotypic heterogeneity as an encourager of cancer invasion
Shin, Y., Han, S., Chung, E., & Chung, S. H. (2014) · Integrative Biology · doi:10.1039/c4ib00022f · Cited by 32 · see citing works
Bertulli, C., Gerigk, M., Piano, N., Liu, Y., Zhang, D., Müller, T. H., Knowles, T. P. J., & Huang, Y. Y. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30776-0 · Cited by 32 · see citing works
Davey, S. K., Aung, A., Agrawal, G., Lim, H. L., Kar, M., & Varghese, S. (2015) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2015.0179 · Cited by 30 · see citing works
Yada, R. C., Desa, D. E., Gillette, A. A., Bartels, E., Harari, P. M., Skala, M. C., Beebe, D. J., & Kerr, S. C. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122136 · Cited by 30 · see citing works
Microengineered 3D collagen gels with independently tunable fiber anisotropy and directionality
Ahmed, A., Joshi, I. M., Larson, S., Mansouri, M., Gholizadeh, S., Allahyari, Z., Forouzandeh, F., Borkholder, D. A., Gaborski, T. R., & Abhyankar, V. V. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202001186 · Cited by 27 · see citing works
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 26 · see citing works
Engineering a Vascularized Hypoxic Tumor Model for Therapeutic Assessment
Ando, Y., Oh, J. M., Zhao, W., Tran, M., & Shen, K. (2021) · Cells · doi:10.3390/cells10092201 · Cited by 24 · see citing works
Beunk, L., Bakker, G., van Ens, D., Bugter, J. M., Gal, F., Svoreň, M., Friedl, P., & Wolf, K. (2022) · The European Physical Journal E · doi:10.1140/epje/s10189-022-00182-6 · Cited by 20 · see citing works
Self-citationIn Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor
Radke, L., Sandig, G., Lubitz, A., Schließer, U., von Horsten, H. H., Blanchard, V., Keil, K., Sandig, V., Giese, C., Hummel, M., et al. (2017) · Bioengineering · doi:10.3390/bioengineering4030070 · Cited by 10 · see citing works
Offeddu, G. S., Cambria, E., Shelton, S. E., Wan, Z., Haase, K., Possenti, L., Nguyen, H. T., Gillrie, M. R., Hickman, D., Knutson, C. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.12.472296 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research
Rauner, G., Gupta, P. B., & Kuperwasser, C. (2025) · Nature Methods · doi:10.1038/s41592-025-02769-1 · Cited by 73 · see citing works
Organ-on-a-Chip Applications in Microfluidic Platforms
An, L., Liu, Y., & Liu, Y. (2025) · Micromachines · doi:10.3390/mi16020201 · Cited by 63 · see citing works
Tumor-microenvironment-on-a-chip: the construction and application
Xu, H., Wen, J., Yang, J., Zhou, S., Li, Y., Xu, K., Li, W., & Li, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01884-4 · Cited by 54 · see citing works
Advances in 3D Organoids and Organ‐on‐a‐Chip Systems for Biomedical Research
Sakthivel, V., Dharshan, S. S., Namasivayam, S. K. R., & Arockiaraj, J. (2026) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbma.70028 · Cited by 47 · see citing works
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 47 · see citing works
Nanomedicine for cancer patient‐centered care
Sorrentino, C., Ciummo, S. L., Fieni, C., & Carlo, E. D. (2024) · MedComm · doi:10.1002/mco2.767 · Cited by 41 · see citing works
How organ-on-a-chip is advancing cancer research and oncology - a cancer hallmarks’ perspective
Avula, L. R., & Grodzinski, P. A. (2024) · Frontiers in Lab on a Chip Technologies · doi:10.3389/frlct.2024.1487377 · Cited by 21 · see citing works
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1462293 · Cited by 19 · see citing works
Emerging tumor hypoxia-relieving nanotherapeutics for boosting photodynamic therapy
Yang, F., Chen, F., Li, S., Wang, S., Peng, L., Deng, S., Zhang, F., Jeschke, U., Wang, Y., & Luo, C. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.163962 · Cited by 18 · see citing works
Advances and applications of organ-on-a-chip technology
Kong, J. S., Kim, J., Jang, J., & Cho, D.-W. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101361 · Cited by 17 · see citing works
Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology
Shukla, A. K., Yoon, S., Oh, S., Lee, D., Ahn, M., & Kim, B. S. (2024) · Biomimetics · doi:10.3390/biomimetics9050306 · Cited by 15 · see citing works
Recent advances in micro-physiological systems for investigating tumor metastasis and organotropism
Yoon, H., del Río, J. S., Cho, S. W., & Park, T. (2024) · Lab on a Chip · doi:10.1039/d3lc01033c · Cited by 13 · see citing works
Nasiri, R., Sankaranthi, A., & Pratx, G. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.002 · Cited by 13 · see citing works
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 12 · see citing works
“In the future, these organotypic platforms might serve as diverse metastatic organs for examining the immune system ’ s role in the premetastatic niche and its contribution to facilitating metastasis (Jouybar et al., 2023).”
BackgroundZimina, T. M., Sitkov, N. O., Газинурович, Г. К., Mikhailova, N., Combs, S. E., & Shevtsov, M. A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1452298 · Cited by 13 · see citing works
Bisconti, F., Abreu, H., Nguyen, T. D., Stolfi, F., Corbezzolo, N., Gigli, G., Raineri, D., Cappellano, G., Polini, A., Gervaso, F., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712796 · Cited by 9 · see citing works
The use of microphysiological systems to model metastatic cancer
Jackson, C. E., Green, N. H., English, W., & Claeyssens, F. (2024) · Biofabrication · doi:10.1088/1758-5090/ad3b70 · Cited by 9 · see citing works
Advancements in Microfluidic Organ-on-a-chip for Oral Medicine
Fan, S., Ge, Y., Li, B., Liu, P., & Liu, X. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.100925 · Cited by 8 · see citing works
Wu, L., Lin, B., Fan, H., & Li, Y. (2025) · Lab on a Chip · doi:10.1039/d5lc00799b · Cited by 9 · see citing works
Engineering tumor spatial heterogeneity in vitro
Chen, C., Zhao, Z., Seah, D. H., Wu, K. Z., Mohanaselvi, S., & Fong, E. L. S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115757 · Cited by 9 · see citing works
Tumor-on-chip’s alliance with molecular pathology against metastatic disease
Carlo, E. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01209-8 · Cited by 9 · see citing works
Tumor-on-chip platforms for breast cancer continuum concept modeling
Neagu, A.-N., Whitham, D., Bruno, P. S., Versaci, N., Biggers, P., & Darie, C. C. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1436393 · Cited by 7 · see citing works
Development of a Bladder Cancer-on-a-Chip Model to Assess Bladder Cancer Cell Invasiveness
Ewell, D. J., Vue, N., Moinuddin, S. M., Sarkar, T., Ahsan, F., & Vinall, R. L. (2024) · Cancers · doi:10.3390/cancers16152657 · Cited by 6 · see citing works
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
Liang, A., Tao, T., Chen, J., Yang, Y., Zhou, X., Zhu, X. M., & Yu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104716 · Cited by 6 · see citing works
Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology
Jeong, W., & Lee, S. J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503104 · Cited by 6 · see citing works
Jouybar, M., Mikula, A. M., Zuidmeer, N., Konijn, T., de Jonge, A. V., Roest, H. P., Mutis, T., van der Laan, L. J. W., Mebius, R. E., den Toonder, J. M. J., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101544 · Cited by 6 · see citing works
Self-citationScaffolds Mimicking the Tumor Microenvironment for In Vitro Malignancy Models
Rosellini, E., & Cascone, M. G. (2025) · Biomimetics · doi:10.3390/biomimetics10100695 · Cited by 5 · see citing works
Ex Vivo Model of Breast Cancer Cell Invasion in Live Lymph Node Tissue
Morgaenko, K., Arneja, A., Ball, A. G., Putelo, A. M., Munson, J. M., Rutkowski, M. R., & Pompano, R. R. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00431 · Cited by 5 · see citing works
Morrison, A. I., Jäger, J., de Winde, C. M., Konijn, T., Roest, H. P., van der Laan, L. J. W., Gibbs, S., Koning, J. J., & Mebius, R. E. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102326 · Cited by 5 · see citing works
Self-citationHost-microbe-cancer interactions on-a-chip
Sousa, M. G. C., Brasino, D. S. K., Krieger, M., Dindar, D. A., Duhen, R., Zhang, Z., França, C. M., & Bertassoni, L. E. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1505963 · Cited by 5 · see citing works
Saffar, S., Ghiaseddin, A., Irani, S., & Hamidieh, A. A. (2025) · Cells · doi:10.3390/cells14090676 · Cited by 4 · see citing works
Advancements in organoid models emulating metastatic niches
Baumann, Z., Billy, É., & Scheidmann, M. C. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.005 · Cited by 4 · see citing works
Miller, P. G., Huang, E. H., Fisher, R. C., & Shuler, M. L. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28890 · Cited by 4 · see citing works
Zhang, J., Sun, M., Zhang, F., Xuanyuan, T., Liu, X., Yu, D., & Liu, W. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501105 · Cited by 4 · see citing works
Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects
Lim, S. Y., Aboelnasr, L. S., & El-Bahrawy, M. A. (2025) · Cancers · doi:10.3390/cancers17193239 · Cited by 3 · see citing works
Elton, E., Strelez, C., Ung, N. M., Perez, R. G., Ghaffarian, K., Hixon, D., Matasci, N., & Mumenthaler, S. M. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100163 · Cited by 3 · see citing works
Jouybar, M., van der Kallen, S., Moradi, H., Zuo, P., Stassen, O. M. J. A., & den Toonder, J. M. J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101926 · Cited by 2 · see citing works
Self-citationYang, Q., He, Y., Wang, S., Li, Z. T., Wang, J., Sun, Z., Yang, W., Zhong, X., Peng, B., Chen, Z., et al. (2025) · Angiogenesis · doi:10.1007/s10456-025-10010-y · Cited by 2 · see citing works
Yisa, B. M., Aselebe, L. O., Adeosun, A. T., Ali, M. J., & Ibitoye, M. O. (2026) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-025-15214-4 · Cited by 2 · see citing works
Alatawi, H., Nair, H. H., Raza, A., Vélez, E. D., Sharma, A. K., & Narayan, S. (2026) · Cancers · doi:10.3390/cancers18071166 · Cited by 2 · see citing works
Colorectal cancer: Current status of preclinical research
Agyarko, E., Tagoe, B., Dankyi, B. O., Quaye, B., Fredua‐Agyeman, M., & Amponsah, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31656-2.00010-4 · Cited by 1 · see citing works
Fuel, form, and memory: The motility-driven journey of cancer cells
Trenado-Yuste, C., & Nelson, C. M. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100624 · Cited by 1 · see citing works
Konopka, J., Roszczyk, J., Jastrzębska, E., & Żuchowska, A. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102890 · Cited by 1 · see citing works
Peptide Arrays as Tools for Unraveling Tumor Microenvironments and Drug Discovery in Oncology
Grab, A. L., Reißfelder, C., & Nesterov‐Mueller, A. (2026) · Cells · doi:10.3390/cells15020146 · Cited by 1 · see citing works
Matrix–Matrix Interfaces Orchestrate Early Mechanosensitive Transition from Attractor To Track
Chen, H.-P., Ngo, T. K. N., Mao, B.-H., Jang, H., Shin, S., Kamm, R. D., Chung, S. H., & Tu, T. (2026) · BioChip Journal · doi:10.1007/s13206-026-00256-z · Cited by 1 · see citing works
Yang, P., Zhu, X., Li, Y., Feng, H., Deng, Y., Zhou, Y., Shao, M., & Ji, B. (2026) · MethodsX · doi:10.1016/j.mex.2026.103832 · Cited by 1 · see citing works
Pasquarelli, A., Cavassi, E., Bucchi, L., Boanini, E., Pompo, G. D., Lipreri, M. V., Perut, F., Bouidida, Y., Sonveaux, P., Rubini, K., et al. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.04.019 · Cited by 1 · see citing works
The Tumor Microenvironment: Translating Intravital Insights into Microphysiological Systems
Imparato, G., Mazio, C., Nevola, P., & Netti, P. A. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00910-4 · Cited by 1 · see citing works
Microengineered Breast Cancer Models: Shaping the Future of Personalized Oncology
Popoiu, T.-A., Cîmpean, A. M., Bojin, F. M., Cerbu, S., Gug, M.-C., Pirvu, C.-A., Pantea, Ș., & Neagu, A. (2025) · Cancers · doi:10.3390/cancers17193160 · Cited by 1 · see citing works
A breast Duct-on-Chip model for emulating invasive ductal carcinoma and testing therapiesPreprint
Jouybar, M., & den Toonder, J. M. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.24.655087
Self-citationA Pan-Cancer Ex Vivo Drug Screen Atlas for Functional Precision OncologyPreprint
Pichotta, K., White, J. B., Quinn, J. F., Markus, A., Tosh, C., de Mathelin, A., Coyne, E. M., Huang, F., & Tansey, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705918
Lu, J., Huang, Y., Ma, S., Hu, S., Xuzhan, L., Huang, Y., Wu, B., Hu, Z., Zhao, C., Huang, J., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02185-5
The hybrid preclinical ecosystem: a strategic road map for oncology clinical translation
Yoo, W. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag173
Deng, B., Ma, Y., Huang, W. Y., Xian, X., Ding, Y., Lu, Y., Yang, Y., Guo, W., Mao, L., Wang, X., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed7050
Amato, D., D’Amico, G., Calderaro, S., Vitale, A. M., Veiceschi, P., Cappello, F., Bavisotto, C. C., & Bosco, G. L. (2026) · Cells · doi:10.3390/cells15121080
Biomaterial-based Platforms for Modeling the Pre-metastatic Niche
Halim, M. S. A., Nadernezhad, A., Kopecky, C., Hauser, S., Kilian, K. A., & Loessner, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30151-3.00005-x
Organoid-Based Miniaturized Bioreactors in Drug Development and Drug Screening
Sah, H., Kumar, D., Sharma, P., Yadav, V., Vasisht, P., Shingatgeri, V., & Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-22332-6_13
Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling
Strepi, K., Koppenol, R. F., Jonkers, J., & Houthuijzen, J. M. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.07.002
From In-Vitro Systems to Patient-Derived Xenografts
Gull, S. A., Khan, A., Ali, M., Sani, A., Almanza-Arjona, Y. C., & Furqan, C. M. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-9848-8.ch010
Han, X., Chen, Q., Li, K., Wu, J., Wang, A., Wang, Y., Zhao, H., & Liu, W. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01401-2
Mansi, S., Halbherr, S., Möller, F., Ernst, A. L., Bauer, S., Kuznetsova, Z., Samsarelou, M. K., Rickert, C. A., Heinrich, D., Zhong, Z., et al. (2026) · Small Science · doi:10.1002/smsc.70371
Pinon, L., Debache, A., Thuaud, A., Tiraboschi, L., Vella, G., Riou-Ramon, J., Cordier, C., Helal, C., Hersen, P., Rescigno, M., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10675-1
Sun, H., Liu, K., Wang, J., Qi, H., Gan, P., Hu, W., Sun, H., Wang, Y., & Liang, Q. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101801
Integrating Technologies for Synthetic, Systems, and Spatial Approaches in Cancer Research
Haynes, K. A., Adebowale, K., Akpa, B. S., Bader, J. S., Bansal, T., Breunig, J. J., Brosh, R., Bugaj, L. J., Burslem, G. M., Chadha, A., et al. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00339
Krebs, C. E., Tripodi, I. J., Pound, P., Baron, R., Pistollato, F., & Constantino, H. (2026) · Research Evaluation · doi:10.1093/reseval/rvag063
- Authors
- Jouybar, M., de Winde, C. M., Wolf, K., Friedl, P., Mebius, R. E., & den Toonder, J. M. J.
- Affiliations
- Eindhoven University of Technology (NL)
- Radboud University Nijmegen (NL)
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Center Amsterdam (NL)
- ORCID
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 42
- Issue
- 4
- Pages
- 431-448
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W4388049884
- Semantic Scholar
- 28ea0016793c4daa379635e904063f19ab5ee0b7
- Cited by
- 66
- References
- 124
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 13
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Trends in biotechnology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- TU/e Research Portal (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Science-XL 2019.022, XL 2019.022, H2020-ECSEL-2019-IA-876190, 14641, 2019.022)
- Electronic Components and Systems for European Leadership (H2020-ECSEL-2019-IA- 876190, 876190)
- Cancer Center Amsterdam (CCA2020-9-73, CCA2019-9-57)
- Horizon 2020 Framework Programme (H2020‐ECSEL‐2019‐IA‐876190)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- metastasis, tumor microenvironment, microfluidics, extracellular matrix, tumor vasculature, tumor immune system, cancer therapy development
- MeSH terms
- Extracellular Matrix, Humans, Neoplasms, Microfluidics, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-07.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-07.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review